Inovio Pharmaceuticals Continues Building Its Senior Team With the Appointment of VP of Quality

Immunotherapy and Vaccine Leader Also Promotes Three Executives in Legal, Clinical and Investor Relations April 1, 2014 Inovio Pharmaceuticals, Inc. today announced the appointment of E.J. Brandreth as Vice President of Quality. He will be responsible for all quality and compliance functions for a company that is moving forward with numerous late and early stage clinical trials and scaling up manufacturing and …

Inovio Pharmaceuticals Recognized with “Best Therapeutic Vaccine” Award at World Vaccine Congress 2014

Biotech Judged First-in-Class for Cervical Pre-Cancer Immunotherapy (VGX-3100), Which Reports Phase II Results Mid-year 2014 Also Awarded “Best Vaccine Licensing Deal” and “Best Early Stage Biotech” March 26, 2014 Inovio Pharmaceuticals, Inc. today announced that it was recognized with three industry awards at the World Vaccine Congress, which is being held this week in Washington, D.C. The Vaccine Industry Excellence …

Interview: Analysing the potential for DNA vaccines

Dr. Niranjan Sardesai, Chief Operating Officer, Inovio Pharmaceuticals was kind enough to take the time to speak to us to give his viewpoint on DNA Vaccines, in particular, their potential across a range of cancer indication. What is the potential for DNA vaccines across a broad range of cancer indications? It’s a great time to be in the DNA vaccine arena. There’s a …